Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight.
The ability of amylin to reduce acute food intake in rodents is well established. Longer-term administration in rats (up to 24 days) shows a concomitant reduction in body weight, suggesting energy intake plays a significant role in mediating amylin-induced weight loss. The current set of experiments further explores the long-term effects of amylin (4-11 wk) on food preference, energy expenditure, and body weight and composition. Furthermore, we describe the acute effect of amylin on locomotor activity and kaolin consumption to test for possible nonhomeostatic mechanisms that could affect food intake. Four-week subcutaneous amylin infusion of high-fat fed rats (3-300 microg.kg(-1).day(-1)) dose dependently reduced food intake and body weight gain (ED(50) for body weight gain = 16.5 microg.kg(-1).day(-1)). The effect of amylin on body weight gain was durable for up to 11 wks and was associated with a specific loss of fat mass and increased metabolic rate. The body weight of rats withdrawn from amylin (100 microg.kg(-1).day(-1)) after 4 wks of infusion returned to control levels 2 wks after treatment cessation, but did not rebound above control levels. When self-selecting calories from a low- or high-fat diet during 11 wks of infusion, amylin-treated rats (300 microg.kg(-1).day(-1)) consistently chose a larger percentage of calories from the low-fat diet vs. controls. Amylin acutely had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. These results demonstrate pharmacological actions of amylin in long-term body weight regulation in part through appetitive-related mechanisms and possibly via changes in food preference and energy expenditure.
Mack
Christine
C
Amylin Pharmaceuticals, Inc., 9360 Towne Centre Dr., San Diego, CA 92121, USA. christine.mack@amylin.com
Wilson
Julie
J
Athanacio
Jennifer
J
Reynolds
James
J
Laugero
Kevin
K
Guss
Stacy
S
Vu
Calvin
C
Roth
Jonathan
J
Parkes
David
D
D000682:Amyloid / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D004032:Diet; D004041:Dietary Fats; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects*; D004734:Energy Metabolism / Q000187:drug effects; D005518:Food Preferences / Q000187:drug effects*; D058228:Islet Amyloid Polypeptide; D007616:Kaolin / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012528:Satiety Response / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects
D000682:Amyloid; D004041:Dietary Fats; D058228:Islet Amyloid Polypeptide; D007616:Kaolin